{"nctId":"NCT02753699","briefTitle":"Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients","startDateStruct":{"date":"2011-12"},"conditions":["Hepatitis C"],"count":723,"armGroups":[{"label":"From Study 2210","type":"EXPERIMENTAL","interventionNames":["Drug: Alisporivir"]},{"label":"From Study 2301","type":"EXPERIMENTAL","interventionNames":["Drug: Alisporivir"]},{"label":"From Study 2211","type":"EXPERIMENTAL","interventionNames":["Drug: Alisporivir"]}],"interventions":[{"name":"Alisporivir","otherNames":["DEB025","Debio 025","ALV"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Provides written informed consent before any assessment is performed\n2. Is male or female aged â‰¥18\n3. Has previously completed a Novartis-sponsored hepatitis C study and received alisporivir\n4. Has achieved SVR24\n5. Is able to comply with the visit schedule\n\nExclusion Criteria:\n\n1. Use of any investigational drugs within 5 half-lives of enrollment, or within 30 days of that medication, whichever is longer.\n2. Use or planned use to start a new course of hepatitis C therapy.\n3. No additional exclusions are to be applied by the Investigator, in order to ensure that the study population is representative of all eligible patients.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Maintaining Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Load Below the Level of Quantification (LOQ) Through Week 48","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.7","spread":null},{"groupId":"OG001","value":"99.5","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"98.0","spread":null},{"groupId":"OG003","value":"99.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.7","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.9","spread":null},{"groupId":"OG001","value":"99.2","spread":null},{"groupId":"OG002","value":"98.1","spread":null},{"groupId":"OG003","value":"99.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Normal Alanine-aminotransferase (ALT) Values at Week 48.","description":"Note that the 24-week period between end of feeder study (SVR24) and first visit in this follow-up study is not counted in the 48 weeks, so this timepoint corresponds to 96 weeks (=24+24+48) after the last dose of alisporivir.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.8","spread":null},{"groupId":"OG001","value":"94.0","spread":null},{"groupId":"OG002","value":"96.0","spread":null},{"groupId":"OG003","value":"95.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.0","spread":null},{"groupId":"OG001","value":"93.9","spread":null},{"groupId":"OG002","value":"82.0","spread":null},{"groupId":"OG003","value":"89.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.2","spread":null},{"groupId":"OG001","value":"91.5","spread":null},{"groupId":"OG002","value":"87.2","spread":null},{"groupId":"OG003","value":"91.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"94.4","spread":null},{"groupId":"OG003","value":"93.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.9","spread":null},{"groupId":"OG001","value":"88.5","spread":null},{"groupId":"OG002","value":"78.8","spread":null},{"groupId":"OG003","value":"83.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":164},"commonTop":[]}}}